NDAORALCAPSULE, DELAYED RELEASEPriority Review
Approved
Oct 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
ENTOCORT EC (budesonide) by Design Pharmaceuticals is corticosteroid hormone receptor agonists [moa]. Approved for asthma, chronic obstructive pulmonary disease, ulcerative colitis. First approved in 2001.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENTOCORT EC is an oral delayed-release corticosteroid containing budesonide, a corticosteroid hormone receptor agonist approved in 2001. It treats multiple inflammatory conditions across respiratory, gastrointestinal, and immunological systems including asthma, COPD, ulcerative colitis, eosinophilic esophagitis, and IgA nephropathy. The drug works by activating corticosteroid receptors to suppress inflammation at the site of disease.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team consolidation or transition to generic/lifecycle management strategies.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications (3)
Worked on ENTOCORT EC at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.